Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPRC | P08575 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.40 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | CFTR | P13569 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31278141 | 0.82 | ACHE (0.55) | ACHETSHRMAPTKMT2AMEN1 | |
| SCHEMBL6382066 | 0.82 | ACHE (0.60) | ACHEMAPTLMNAKDM4EPOLB | |
| SCHEMBL4017850 | 0.81 | ACHE (0.41) | ACHEMAPTKMT2AMEN1LMNA | |
| SCHEMBL30967887 | 0.81 | ACHE (0.41) | ACHEMAPTKMT2AMEN1LMNA | |
| SCHEMBL4018743 | 0.81 | ACHE (0.41) | ACHEMAPTKMT2AMEN1LMNA | |
| SCHEMBL23856945 | 0.81 | TSHR (0.41) | ACHETSHRMAPTKMT2AMEN1 | |
| SCHEMBL28546898 | 0.78 | ACHE (0.44) | PTPRCACHEMAPTKMT2AMEN1 | |
| SCHEMBL29476747 | 0.74 | ACHE (0.51) | ACHEMAPTKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL1000380 | 0.74 | ACHE (0.51) | ACHEMAPTKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL5953006 | 0.73 | ACHE (0.56) | PTPRCACHETSHRMAPTMAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12479807-B2 | Methods using HDAC11 inhibitors | VALO HEALTH, INC. (US) | 2025-11-25 | — | — | US | disclosed |
| US-20220235018-A1 | METHODS USING HDAC11 INHIBITORS | Valo Health, LLC | 2022-07-28 | — | — | US | disclosed |
| US-11345672-B2 | Methods using HDAC11 inhibitors | VALO HEALTH, INC. (US) | 2022-05-31 | — | — | US | disclosed |
| US-11345672-B2 | Methods using HDAC11 inhibitors | VALO HEALTH, INC. (US) | 2022-05-31 | — | — | US | disclosed |
| US-20190084946-A1 | METHODS USING HDAC11 INHIBITORS | Valo Health, LLC | 2019-03-21 | — | — | US | disclosed |
| US-20190084945-A1 | METHODS USING HDAC11 INHIBITORS | VALO HEALTH, INC. | 2019-03-21 | — | — | US | disclosed |
| US-20180127386-A1 | METHODS USING HDAC11 INHIBITORS | VALO EARLY DISCOVERY, INC. | 2018-05-10 | — | — | US | disclosed |
| WO-2018075959-A1 | METHODS USING HDAC11 INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2018-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11345672-B2 | Methods using HDAC11 inhibitors | HDAC11, HDAC1, HDAC10 | PTPRC 1785/4885ACHE 4589/4885TSHR 3985/4885 |
| US-20180127386-A1 | METHODS USING HDAC11 INHIBITORS | HDAC11, HDAC1, HDAC10 | PTPRC 1785/4885ACHE 4589/4885TSHR 3985/4885 |
| US-12479807-B2 | Methods using HDAC11 inhibitors | HDAC11, HDAC1, HDAC10 | PTPRC 1785/4885ACHE 4589/4885TSHR 3985/4885 |
| US-20190084945-A1 | METHODS USING HDAC11 INHIBITORS | HDAC11, HDAC1, HDAC10 | PTPRC 1785/4885ACHE 4589/4885TSHR 3985/4885 |
| US-20190084946-A1 | METHODS USING HDAC11 INHIBITORS | HDAC11, HDAC1, HDAC10 | PTPRC 1785/4885ACHE 4589/4885TSHR 3985/4885 |
| US-20220235018-A1 | METHODS USING HDAC11 INHIBITORS | HDAC11, HDAC1, HDAC10 | PTPRC 1785/4885ACHE 4589/4885TSHR 3985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.